Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation

Cancer Genetics and Cytogenetics

Volumn 197, Issue 2, 2010, Pages 107-116

  Souček, Karel ^a   Gajdušková, Pavla ^a   Brázdová, Marie ^a   Hýžd'alová, Martina ^a   Kočí, Lenka ^a   Vydra, David ^b   Trojanec, Radek ^b   Pernicová, Zuzana ^a   Lentvorská, Lenka ^c   Hajdúch, Marián ^b   Hofmanová, Jiřina ^a   Kozubík, Alois ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTIDINE; PROLINE; PROTEIN MDM2; PROTEIN P53;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL STRAIN FHC; CHROMOSOME 8Q; CHROMOSOME DUPLICATION; CHROMOSOME LOSS; CHROMOSOME NUMBER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; FETUS; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SCID MOUSE; SOLID TUMOR; TRIPLOIDY;

ANIMALS; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLONIC NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETIC ANALYSIS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; FEMALE; FETUS; GENES, P53; HCT116 CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; KERATINS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PHENOTYPE; SIGNAL TRANSDUCTION;

MUS;

EID: 77249178774     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.11.009     Document Type: Article

References (37)

1. Sinisi A.A., Chieffi P., Pasquali D., Kisslinger A., Staibano S., Bellastella A., and Tramontano D. EPN: a novel epithelial cell line derived from human prostate tissue. In Vitro Cell Dev Biol Anim 38 (2002) 165-172
2. Soule H.D., Maloney T.M., Wolman S.R., Peterson Jr. W.D., Brenz R., McGrath C.M., Russo J., Pauley R.J., Jones R.F., and Brooks S.C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50 (1990) 6075-6086
3. Forsyth N.R., Morales C.P., Damle S., Boman B., Wright W.E., Kopelovich L., and Shay J.W. Spontaneous immortalization of clinically normal colon-derived fibroblasts from a familial adenomatous polyposis patient. Neoplasia 6 (2004) 258-265
4. Fridman A.L., and Tainsky M.A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27 (2008) 5975-5987
5. Marella N.V., Malyavantham K.S., Wang J., Matsui S.-i., Liang P., and Berezney R. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. Cancer Res 69 (2009) 5946-5953
6. Worsham M., Pals G., Schouten J., Miller F., Tiwari N., van Spaendonk R., and Wolman S. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96 (2006) 177-186
7. Nimesh B., Kah Wai L., Aude G., Hanna W., Ulf H., and Serhiy S. Comparative proteome profiling of MCF10A and 184A1 human breast epithelial cells emphasized involvement of CDK4 and cyclin D3 in cell proliferation. Proteomics Clin Appl 3 (2009) 68-77
8. Proby C.M., Purdie K.J., Sexton C.J., Purkis P., Navsaria H.A., Stables J.N., and Leigh I.M. Spontaneous keratinocyte cell lines representing early and advanced stages of malignant transformation of the epidermis. Exp Dermatol 9 (2000) 104-117
9. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
10. Siddiqui K.M., and Chopra D.P. Primary and long term epithelial cell cultures from human fetal normal colonic mucosa. In Vitro 20 (1984) 859-868
11. Zhu S., Bjorge J.D., Cheng H.C., and Fujita D.J. Decreased CHK protein levels are associated with Src activation in colon cancer cells. Oncogene 27 (2008) 2027-2034
12. Zhu S., Bjorge J.D., and Fujita D.J. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 67 (2007) 10129-10137
13. Shimizu M., Deguchi A., Lim J.T., Moriwaki H., Kopelovich L., and Weinstein I.B. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11 (2005) 2735-2746
14. Hofmanova J., Vaculova A., Hyzd'alova M., and Kozubik A. Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers. Oncol Rep 19 (2008) 567-573
15. Hyzd'alova M., Hofmanova J., Pachernik J., Vaculova A., and Kozubik A. The interaction of butyrate with TNF-alpha during differentiation and apoptosis of colon epithelial cells: role of NF-kappaB activation. Cytokine 44 (2008) 33-43
16. Fajkus J., Borsky M., Kunicka Z., Kovarikova M., Dvorakova D., Hofmanova J., and Kozubik A. Changes in telomerase activity, expression and splicing in response to differentiation of normal and carcinoma colon cells. Anticancer Res 23 (2003) 1605-1612
17. Jain A.N., Tokuyasu T.A., Snijders A.M., Segraves R., Albertson D.G., and Pinkel D. Fully automatic quantification of microarray image data. Genome Res 12 (2002) 325-332
18. Hammarström S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9 (1999) 67-81
19. Kang W.Y., Chen W.T., Wu M.T., and Chai C.Y. The expression of CD66a and possible roles in colorectal adenoma and adenocarcinoma. Int J Colorectal Dis 22 (2007) 869-874
20. Snijders A.M., Fridlyand J., Mans D.A., Segraves R., Jain A.N., Pinkel D., and Albertson D.G. Shaping of tumor and drug-resistant genomes by instability and selection. Oncogene 22 (2003) 4370-4379
21. Douglas E.J., Fiegler H., Rowan A., Halford S., Bicknell D.C., Bodmer W., Tomlinson I.P., and Carter N.P. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res 64 (2004) 4817-4825
22. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
23. Stewart S.A., and Weinberg R.A. Telomeres: cancer to human aging. Annu Rev Cell Dev Biol 22 (2006) 531
24. Shats I., Milyavsky M., Tang X., Stambolsky P., Erez N., Brosh R., Kogan I., Braunstein I., Tzukerman M., Ginsberg D., and Rotter V. p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 279 (2004) 50976-50985
25. Scian M.J., Stagliano K.E., Deb D., Ellis M.A., Carchman E.H., Das A., Valerie K., Deb S.P., and Deb S. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 23 (2004) 4430-4443
26. Greenberg R.A., O'Hagan R.C., Deng H., Xiao Q., Hann S.R., Adams R.R., Lichtsteiner S., Chin L., Morin G.B., and DePinho R.A. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18 (1999) 1219-1226
27. Felsher D.W., and Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 96 (1999) 3940-3944
28. Nasif W.A., Lotfy M., El-Sayed I.H., El-Kenawy Ael M., El-Shahat M., and El-Hak N.G. Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer. Med Oncol 23 (2006) 237-244
29. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28 (2007) 622-629
30. Petitjean A., Achatz M.I.W., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 (2007) 2157-2165
31. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 (2003) 403-410
32. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
33. Koushik A., Tranah G.J., Ma J., Stampfer M.J., Sesso H.D., Fuchs C.S., Giovannucci E.L., and Hunter D.J. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 119 (2006) 1863-1868
34. Sjalander A., Birgander R., Saha N., Beckman L., and Beckman G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 46 (1996) 41-48
35. Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutierrez-Enriquez S., Hall J., Guino E., Peinado M.A., Capella G., and Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23 (2004) 1954-1956
36. Schneider-Stock R., Boltze C., Peters B., Szibor R., Landt O., Meyer F., and Roessner A. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6 (2004) 529-535
37. Berglund L., Bjorling E., Oksvold P., Fagerberg L., Asplund A., Szigyarto C.A., Persson A., Ottosson J., Wernerus H., Nilsson P., Lundberg E., Sivertsson A., Navani S., Wester K., Kampf C., Hober S., Ponten F., and Uhlen M. A genecentric human protein atlas for expression profiles based on antibodies. Mol Cell Proteomics 7 (2008) 2019-2027